The journalist from Fox News went to Project Veritas to discuss the censorship of the coronavirus medicament treatment coverage. She’s Ivory Hecker and ended her collaboration with Fox News. That didn’t stop her from sharing the truth!
Now, she’s here with her last report, independent, and she’s diving into the alternative coronavirus treatments. She interviewed Dr. Joseph Varon, Houston, Texas’s chief medical officer.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
My first independent report just hit 100,000 views. Thanks y’all https://t.co/1XHZYrtGHy
— Ivory Hecker (@IvoryHecker) June 26, 2021
He spent 400 days examining the coronavirus and revealed some interesting findings. But, when he tried to show his discoveries, he was censored.
The mass media weren’t prepared to reveal the big truth and that his drug gave excellent results.
Why was he censored?
He used the Math + protocol during his examinations. It prioritizes steroids and blood thinners in combination with vitamins via IC and Ivermectin. According to the doctor, this drug was the reason why there was a tremendous success rate.
Take a look at the video below.
Maybe Dr. Varon’s studies are a threat to the pharmaceutical industry! If Ivermectin is used as a treatment for COVID-19, then the vaccine won’t be needed anymore.
However, Ivermectin is a successful drug against this disease, and Dr. Varon wanted the world to know about that. In the UK, there were numerous studies about Ivermenctin’s efficacy in COVID-19 treatment.
Yahoo News covered this story.
Ivermectin, a widely used anti-parasitic drug, is to be investigated as a possible treatment for Covid-19, researchers have announced.
The drug, used across the world to treat parasitic infections, will be studied as part of Oxford University’s Principle trial – which is dedicated to finding at-home medicine for speeding up recovery from or preventing hospitalisation with Covid-19.
Ivermectin has been controversially touted as a potential treatment for Covid since the earliest stages of the pandemic.
Although the drug is not an antiviral, laboratory-based studies have found that it can block replication of Sars-CoV-2 – the virus that causes Covid-19 – but at much higher, and unsafe, concentrations than those used in currently authorised ivermectin treatments.
Results from clinical studies were varied, with some studies showing no effect and others reporting that ivermectin has a potential benefit, in terms of reducing viral load and the duration of symptoms in some patients with mild Covid.
However, the lack of evidence from large-scale, randomised controlled trials has made it impossible to say with confidence that the drug is effective in treating Covid – though some countries, such as Peru, Bolivia and Colombia, have decided to nonetheless push ahead with administering ivermectin to patients.
The US Food and Drug Administration has previously warned against using ivermectin to treat or prevent Covid-19, while a European Medicines Agency review in March concluded that “the available data do not support its use for Covid-19 outside well-designed clinical trials”.
Oxford’s professor Chris Butler, the joint chief investigator of the Principle trial, said his team hopes “to generate robust evidence to determine how effective the treatment is against Covid-19, and whether there are benefits or harms associated with its use.”
He said the drug is readily available on a global level and is well known to have a “good safety profile”.
Participants enrolled in the study will be randomly assigned a three-day course of ivermectin treatment. They will be followed-up for 28 days and will be compared with trialists who receive the usual standard of NHS care only.
Dr Stephen Griffin, a virologist at the University of Leeds, said the drug’s inclusion in the Principle trial “should provide a final answer to the questions over whether this drug might be repurposed as an antiviral targeting Sars-CoV-2”.
“Much like hydroxychloroquine before, there has been a considerable amount of off-label use of this drug, based primarily upon in vitro cell culture data,” he said.
“However, antiviral effects have only been demonstrated in such systems at concentrations much higher than those corresponding to routine anti-parasitic treatment.”
Ivermectin is the seventh treatment to be investigated by the Principle trial, and is being evaluated alongside the influenza antiviral favipiravir.
In April, researchers from the study found that budesonide, a medicine used for asthma, can shorten the recovery time of Covid-19 sufferers who do not need hospital treatment by an average of three days.
The readily available drug, administered via a cheap inhaler twice a day for up to 14 days, is being prescribed by GPs on a “case-by-case basis”, allowing doctors to treat Covid-19 patients at home.
Ivermectin’s admission to the Principle trial will be closely monitored by the government’s taskforce dedicated to searching and developing a new generation of drugs capable of treating people with coronavirus in their own homes.
The taskforce, modelled on the team responsible for the UK’s vaccine programme, is aiming to identify and support research into promising antiviral treatments that can reduce transmission and speed up recovery from Covid-19.
It’s hoped two effective treatments – offered in tablet form – will be made available to the public as early as autumn, providing Britain with “another layer of defence” alongside the vaccines in combating possible future waves and emerging variants, said Sir Patrick Vallance in April.
Indonesia is now testing this drug on the patients.
Eight hospitals in Indonesia are set to conduct clinical trials on Ivermectin, an anti-parasitic medicine that has appeared to be a potential COVID-19 medication, following a permit issued by the national agency of drug and food control (BPOM).
BPOM’s head Penny K. Lukito said at a press conference on Monday that global data and guidelines from the World Health Organization (WHO) show that Ivermectin, previously used for deworming, can also be used for COVID-19 treatment. However, data are still being collected and the results are not conclusive.
Clinical trials are expected to be conducted over a period of three months.
The number of countries that are using Ivermectin as a treatment is growing.
With a third wave of COVID-19 hitting the country, government authorities in Zimbabwe have authorized the use of #ivermectin to stop the rise in case counts, hospitalizations & deaths.
This humanitarian action today will save many lives in Zimbabwe.https://t.co/q3B1OmVLC0
— Frontline Covid-19 Critical Care (@Covid19Critical) June 27, 2021
The Delta variant is the India version- IVERMECTIN squashed this variant in every province it was used in in India- NO MEDIA COVERAGE!! GO to https://t.co/nv5KoK2oNf and stay current on CV 19 treatments!
— Bruce Boros (@BorosBruce) June 26, 2021
Ogni tanto una buona notizia
South Africa Approves Ivermectin; Peer-Reviewed Study Says Can End COVID | Coronavirus News https://t.co/BMP9Y88Grf
— Andrea M. G. G. Stramezzi (@AStramezzi) June 28, 2021
FINLAND MAKE NASAL IVERMECTIN PLUS HCQ AND PROTEASE INHIBITOR DRUG FOR COVID https://t.co/KLSx3YHvWK
— Ricardo ER (@RICNEURO) May 29, 2021
It saves lives, and the mainstream media don’t want to share that! But, they are talking about critical race theory and missing the main point. The true heroes in this war are the doctors who try to find the cure and share it with the world.
— Theoretical Physicist (@TheoreticalPhy6) April 8, 2021